

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0233)**

### **RESUMPTION CONDITIONS**

Reference is made to the announcement of Mingyuan Medicare Development Company Limited (the "Company", together with its subsidiaries, collectively the "Group") dated 17 June 2015 in relation to the delay in publication of annual results of the Group for the year ended 31 December 2014 to enable the establishment of an independent board committee comprising the independent non-executive directors of the Company to appoint an independent third party investigator to perform an independent investigation of the bank balance of a subsidiary (the "Subsidiary") as of 31 December 2014. The bank balance of the Subsidiary as of 31 December 2014 amounts to approximately RMB420 million (the "Bank Balance") and the Company's auditors is unable to verify that the Subsidiary owns the Bank Balance (the "Unresolved Matter").

The board of directors of the Company (the "Board") announces that on 14 July 2015 the Company received a letter from The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), in which the Stock Exchange has imposed the following resumption conditions ("Resumption Conditions") on the Company:

1. conduct a forensic investigation on the Unresolved Matter, disclose the findings of the investigation, assess the impact on the Company's financial and operational positions, and take appropriate remedial actions;
2. publish all outstanding financial results under the Listing Rules and address any audit qualifications;
3. demonstrate that the Company has put in place adequate financial reporting procedures and internal control systems to meet its Listing Rules obligations; and
4. inform the market of all material information for the shareholders and the investors to appraise the Company and the Subsidiaries' position.

The Company must also comply with the Listing Rules and all applicable laws and regulations in Hong Kong and its place of incorporation before resumption. The Stock Exchange may modify any of the above Resumption Conditions and/or impose further conditions if the situation changes.

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2015 and will remain suspended until further notice.

By order of the Board  
**Mingyuan Medicare Development Company Limited**  
銘源醫療發展有限公司<sup>\*</sup>  
**Yao Yuan**  
*Chairman & CEO*

Hong Kong, 15 July 2015

*As at the date of this announcement, the executive director is Mr. Yao Yuan (Chairman & CEO); non-executive director is Mr. Yu Ti Jun; the independent non-executive directors are Mr. Yao Liang and Mr. Yang Chun Bao.*

*\* For identification purposes only*